Your browser doesn't support javascript.
loading
Fitbit Usage in Patients With Breast Cancer Undergoing Chemotherapy.
Dreher, Nickolas; Hadeler, Edward Kenji; Hartman, Sheri J; Wong, Emily C; Acerbi, Irene; Rugo, Hope S; Majure, Melanie Catherine; Chien, Amy Jo; Esserman, Laura J; Melisko, Michelle E.
Afiliación
  • Dreher N; University of California, San Francisco, San Francisco, CA. Electronic address: Nickolas.Dreher@icahn.mssm.edu.
  • Hadeler EK; University of California, San Francisco, San Francisco, CA.
  • Hartman SJ; University of California, San Diego, La Jolla, CA.
  • Wong EC; University of California, San Francisco, San Francisco, CA.
  • Acerbi I; University of California, San Francisco, San Francisco, CA.
  • Rugo HS; University of California, San Francisco, San Francisco, CA.
  • Majure MC; University of California, San Francisco, San Francisco, CA.
  • Chien AJ; University of California, San Francisco, San Francisco, CA.
  • Esserman LJ; University of California, San Francisco, San Francisco, CA.
  • Melisko ME; University of California, San Francisco, San Francisco, CA.
Clin Breast Cancer ; 19(6): 443-449.e1, 2019 12.
Article en En | MEDLINE | ID: mdl-31285177
BACKGROUND: Many patients' activity levels decrease during chemotherapy. Wearable devices, such as Fitbits, track activity patterns and may encourage behavior change. This study aimed to determine the utility of using Fitbits to measure physical activity and sleep throughout chemotherapy. PATIENTS AND METHODS: Patients with early stage breast cancer were enrolled prior to starting chemotherapy. Patients received a Fitbit Charge HR and were instructed to wear it and sync at least weekly throughout chemotherapy and up to 6 months post therapy. Patients completed baseline surveys, and treatment information was collected from their medical records. Fitbit data was downloaded from the Fitabase data management platform. To assess utility, we evaluated how many days patients wore their Fitbit for at least 10 hours. RESULTS: Adherence to wearing the Fitbit was low, with 16.9% of patients never syncing their device. For those who did sync, the mean number of valid days (> 10 hours of use) across the 9-month study period was 44.5% (SD, 36.9%), and the median was 39.6%, with a range of 0% to 100% of the total study days. Adherence was higher among participants receiving adjuvant chemotherapy versus neoadjuvant chemotherapy (51.9% vs. 29.6% valid days, respectively [P = .037]). Baseline questions indicating positive attitudes toward technology were significantly correlated with higher adherence. CONCLUSIONS: Fitbit use during breast cancer chemotherapy was poor in the absence of prompts to encourage wear. Interventions including phone calls, texts, or other reminders to maintain adherence are likely necessary to increase wear in active treatment settings.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Ejercicio Físico / Protocolos de Quimioterapia Combinada Antineoplásica / Monitores de Ejercicio / Monitoreo Fisiológico Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Aspecto: Patient_preference Límite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Clin Breast Cancer Asunto de la revista: NEOPLASIAS Año: 2019 Tipo del documento: Article Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Ejercicio Físico / Protocolos de Quimioterapia Combinada Antineoplásica / Monitores de Ejercicio / Monitoreo Fisiológico Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Aspecto: Patient_preference Límite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Clin Breast Cancer Asunto de la revista: NEOPLASIAS Año: 2019 Tipo del documento: Article Pais de publicación: Estados Unidos